S&P 500   3,978.92 (+0.69%)
DOW   32,411.38 (+0.52%)
QQQ   308.02 (+0.67%)
AAPL   157.89 (+0.31%)
MSFT   271.51 (-0.26%)
META   200.78 (+1.50%)
GOOGL   104.09 (+2.84%)
AMZN   99.66 (+2.00%)
TSLA   194.98 (+6.40%)
NVDA   258.22 (-0.30%)
NIO   9.26 (+5.83%)
BABA   83.24 (+2.77%)
AMD   94.99 (-1.88%)
T   18.49 (+0.00%)
F   11.72 (+4.83%)
MU   58.07 (+0.75%)
CGC   1.98 (+6.45%)
GE   92.39 (+2.75%)
DIS   96.27 (+2.18%)
AMC   4.38 (+2.58%)
PFE   40.50 (-0.76%)
PYPL   75.43 (+3.03%)
NFLX   305.41 (+0.09%)
S&P 500   3,978.92 (+0.69%)
DOW   32,411.38 (+0.52%)
QQQ   308.02 (+0.67%)
AAPL   157.89 (+0.31%)
MSFT   271.51 (-0.26%)
META   200.78 (+1.50%)
GOOGL   104.09 (+2.84%)
AMZN   99.66 (+2.00%)
TSLA   194.98 (+6.40%)
NVDA   258.22 (-0.30%)
NIO   9.26 (+5.83%)
BABA   83.24 (+2.77%)
AMD   94.99 (-1.88%)
T   18.49 (+0.00%)
F   11.72 (+4.83%)
MU   58.07 (+0.75%)
CGC   1.98 (+6.45%)
GE   92.39 (+2.75%)
DIS   96.27 (+2.18%)
AMC   4.38 (+2.58%)
PFE   40.50 (-0.76%)
PYPL   75.43 (+3.03%)
NFLX   305.41 (+0.09%)
S&P 500   3,978.92 (+0.69%)
DOW   32,411.38 (+0.52%)
QQQ   308.02 (+0.67%)
AAPL   157.89 (+0.31%)
MSFT   271.51 (-0.26%)
META   200.78 (+1.50%)
GOOGL   104.09 (+2.84%)
AMZN   99.66 (+2.00%)
TSLA   194.98 (+6.40%)
NVDA   258.22 (-0.30%)
NIO   9.26 (+5.83%)
BABA   83.24 (+2.77%)
AMD   94.99 (-1.88%)
T   18.49 (+0.00%)
F   11.72 (+4.83%)
MU   58.07 (+0.75%)
CGC   1.98 (+6.45%)
GE   92.39 (+2.75%)
DIS   96.27 (+2.18%)
AMC   4.38 (+2.58%)
PFE   40.50 (-0.76%)
PYPL   75.43 (+3.03%)
NFLX   305.41 (+0.09%)
S&P 500   3,978.92 (+0.69%)
DOW   32,411.38 (+0.52%)
QQQ   308.02 (+0.67%)
AAPL   157.89 (+0.31%)
MSFT   271.51 (-0.26%)
META   200.78 (+1.50%)
GOOGL   104.09 (+2.84%)
AMZN   99.66 (+2.00%)
TSLA   194.98 (+6.40%)
NVDA   258.22 (-0.30%)
NIO   9.26 (+5.83%)
BABA   83.24 (+2.77%)
AMD   94.99 (-1.88%)
T   18.49 (+0.00%)
F   11.72 (+4.83%)
MU   58.07 (+0.75%)
CGC   1.98 (+6.45%)
GE   92.39 (+2.75%)
DIS   96.27 (+2.18%)
AMC   4.38 (+2.58%)
PFE   40.50 (-0.76%)
PYPL   75.43 (+3.03%)
NFLX   305.41 (+0.09%)
NASDAQ:ANEB

Anebulo Pharmaceuticals - ANEB News Today

$2.75
-0.12 (-4.18%)
(As of 03/21/2023 11:52 AM ET)
Add
Compare
Today's Range
$2.75
▼
$2.75
50-Day Range
$2.40
▼
$3.25
52-Week Range
$1.77
▼
$7.73
Volume
129 shs
Average Volume
5,454 shs
Market Capitalization
$70.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Get Anebulo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.


ANEB Media Mentions By Week

ANEB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ANEB
News Sentiment
▼
-0.01

0.34
▲
Average
Medical
News Sentiment

ANEB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ANEB Articles
This Week
▼
2

0
▲
ANEB Articles
Average Week

SourceHeadline
MarketBeat logoAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update
americanbankingnews.com - March 18 at 1:44 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions
finance.yahoo.com - March 8 at 4:59 PM
barrons.com logoAnebulo Pharmaceuticals Inc.
barrons.com - February 19 at 1:27 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
finance.yahoo.com - February 10 at 10:45 AM
seekingalpha.com logoAnebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear
seekingalpha.com - January 27 at 8:13 PM
msn.com logoAcute Cannabinoid Intoxication: This Pharma Company's Clinical Trials To Reduce And Treat Symptoms
msn.com - January 9 at 4:51 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
finance.yahoo.com - January 9 at 11:51 AM
finance.yahoo.com logoCompanies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
finance.yahoo.com - December 21 at 8:21 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
finance.yahoo.com - November 10 at 5:37 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
finance.yahoo.com - November 1 at 8:32 PM
finance.yahoo.com logoLower Doses Of Anebulo's ANEB-001 Reduces Negative Effects Of Higher Doses Of THC
finance.yahoo.com - September 26 at 2:31 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
finance.yahoo.com - September 26 at 9:30 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
finance.yahoo.com - September 26 at 9:30 AM
finance.yahoo.com logoAnebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022
finance.yahoo.com - September 20 at 3:25 PM
investing.com logoAnebulo Pharmaceuticals Earnings Miss, Revenue Inline In Q1
investing.com - September 10 at 9:54 PM
seekingalpha.com logoAnebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03
seekingalpha.com - September 10 at 9:54 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
finance.yahoo.com - September 9 at 9:53 AM
finance.yahoo.com logoAnebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
finance.yahoo.com - August 23 at 6:04 PM
benzinga.com logoSuffering From Acute Cannabinoid Intoxication? Anebulo Is Getting Closer To Investigational New Drug Application
benzinga.com - July 7 at 1:25 AM
morningstar.com logoAnebulo Pharmaceuticals Inc - Stock News
morningstar.com - July 6 at 8:25 PM
finance.yahoo.com logoTYME Technologies Shares Surge On Merger Agreement With Syros Pharma
finance.yahoo.com - July 5 at 12:51 PM
markets.businessinsider.com logoWhy U.S. Stocks Are Trading Lower; Tesla Shares Drop After Price Target Cut At JPMorgan
markets.businessinsider.com - July 5 at 12:51 PM
nasdaq.com logoAnebulo Pharma Reports Positive Topline Data For ANEB-001 From Phase 2 Trial
nasdaq.com - July 5 at 12:51 PM
seekingalpha.com logoAnebulo's drug ANEB-001 helps reduce cannabis high in phase 2 study
seekingalpha.com - July 5 at 12:51 PM
finance.yahoo.com logoAnebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants
finance.yahoo.com - July 5 at 12:51 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
finance.yahoo.com - July 5 at 6:29 AM
finance.yahoo.com logoAnebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
finance.yahoo.com - June 23 at 4:10 PM
seekingalpha.com logoAnebulo Pharmaceuticals appoints Kenneth Cundy as chief scientific officer
seekingalpha.com - May 24 at 6:18 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
finance.yahoo.com - May 24 at 6:18 PM
benzinga.com logoAnebulo Pharmaceuticals (NASDAQ:ANEB), Short Interest Report
benzinga.com - May 14 at 8:05 PM
seekingalpha.com logoAnebulo Pharmaceuticals GAAP EPS of -$0.08 misses by $0.03
seekingalpha.com - May 11 at 12:51 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
finance.yahoo.com - May 11 at 12:51 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
finance.yahoo.com - April 1 at 11:46 AM
seekingalpha.com logoAnebulo Pharmaceuticals GAAP EPS of -$0.05
seekingalpha.com - February 13 at 2:43 AM
benzinga.com logoAnebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication
benzinga.com - February 11 at 9:29 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
finance.yahoo.com - February 11 at 8:37 AM
nasdaq.com logoAnebulo Pharmaceuticals (NASDAQ:ANEB) Is In A Good Position To Deliver On Growth Plans
nasdaq.com - February 5 at 6:32 PM
finance.yahoo.com logoWe're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely
finance.yahoo.com - February 4 at 10:46 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
finance.yahoo.com - January 6 at 8:00 AM
finance.yahoo.com logoAnebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
finance.yahoo.com - January 6 at 8:00 AM
marketwatch.com logoAnebulo Pharmaceuticals Names Simon Allen CEO
marketwatch.com - January 4 at 7:46 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
finance.yahoo.com - January 4 at 7:46 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
finance.yahoo.com - January 3 at 11:44 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
finance.yahoo.com - November 12 at 10:06 AM
marketwatch.com logoAnebulo Pharmaceuticals Shares Rise 7% After New Patent
marketwatch.com - October 13 at 2:53 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose
finance.yahoo.com - October 13 at 9:52 AM
finance.yahoo.com logoOverdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem
finance.yahoo.com - October 12 at 1:42 PM
finance.yahoo.com logoAnebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City
finance.yahoo.com - October 5 at 12:17 PM
finance.yahoo.com logoThe Unintended Consequences of Ever-Increasing Marijuana Potency
finance.yahoo.com - September 27 at 12:56 PM
benzinga.com logoCBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
benzinga.com - September 23 at 10:57 AM
Get Anebulo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ANEB) was last updated on 3/21/2023 by MarketBeat.com Staff